{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Esketamine+56+mg", "query": { "intervention": "Esketamine 56 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Esketamine+56+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T13:46:56.428Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02857777", "title": "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 37, "start_date": "2016-08-09", "completion_date": "2017-01-27", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02857777" }, { "nct_id": "NCT01980303", "title": "A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "20 Years to 55 Years" }, "enrollment_count": 29, "start_date": "2013-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980303" }, { "nct_id": "NCT03185819", "title": "Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "Intranasal Placebo", "type": "DRUG" }, { "name": "Midazolam Placebo Solution", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "9 Years to 17 Years" }, "enrollment_count": 147, "start_date": "2017-10-05", "completion_date": "2023-03-31", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 18, "location_summary": "Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Winfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03185819" }, { "nct_id": "NCT02418585", "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Treatment-resistant Depression" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 236, "start_date": "2015-08-07", "completion_date": "2017-11-06", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Orange, California • San Rafael, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Rafael", "state": "California" }, { "city": "Maitland", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418585" }, { "nct_id": "NCT02497287", "title": "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Treatment-resistant Depression" ], "interventions": [ { "name": "Esketamine (Intranasal Spray)", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral Antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 802, "start_date": "2015-09-30", "completion_date": "2017-10-28", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 16, "location_summary": "New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02497287" }, { "nct_id": "NCT03434041", "title": "A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine 56 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral Antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 252, "start_date": "2018-05-25", "completion_date": "2021-04-13", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Gaithersburg", "state": "Maryland" }, { "city": "Watertown", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434041" }, { "nct_id": "NCT02133001", "title": "A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 68, "start_date": "2014-05-23", "completion_date": "2016-02-01", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 14, "location_summary": "Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02133001" }, { "nct_id": "NCT02846519", "title": "Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "20 Years to 55 Years" }, "enrollment_count": 66, "start_date": "2016-02-26", "completion_date": "2016-05-28", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846519" }, { "nct_id": "NCT02493868", "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Duloxetine (Oral Antidepressant)", "type": "DRUG" }, { "name": "Escitalopram (Oral antidepressant)", "type": "DRUG" }, { "name": "Sertraline (Oral Antidepressant)", "type": "DRUG" }, { "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 719, "start_date": "2015-10-01", "completion_date": "2018-02-16", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493868" }, { "nct_id": "NCT04599855", "title": "A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depressive Disorder, Treatment-Resistant" ], "interventions": [ { "name": "Esketamine 56 mg", "type": "DRUG" }, { "name": "Esketamine 84 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 477, "start_date": "2020-11-04", "completion_date": "2024-01-31", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-09-01T13:46:56.428Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599855" } ] }